Cumberland Pharmaceuticals(CPIX) - 2019 Q4 - Earnings Call Presentation

Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company with a portfolio of seven FDA-approved products[3] - The company has several near-term catalysts for new growth opportunities, including Vibativ post-acquisition integration and market expansion, Next Generation Caldolor product, and RediTrex methotrexate product line[3] - Cumberland has five Phase II products in development with upcoming study milestones[3] - The company has a strong financial position and positive net cash flows from operations[3] Product Portfolio and Strategy - The company's mission is to advance patient care through the delivery of high-quality medicines[4] - The company's strategy is to build a portfolio of specialized biopharmaceutical brands through product development and acquisition[4] - The company aims to add one new product per year through business development or internal product development, targeting branded Rx products in hospital acute care or gastroenterology with sales of $5-25 million or larger with attractive margins[8] - Caldolor has administered over 2.3 million doses[6] Financial Overview - In 2019, Cumberland Pharmaceuticals had net revenues of $47.5 million[16] - The company's total assets were $104.5 million and total liabilities were $53.5 million as of December 31, 2019[16] - The company has tax carry forward credits of $44 million available[17]